SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is experiencing intense volatility and downward pressure after Marvell canceled its purchase orders, citing a confidentiality breach caused by the CFO's recent public commentary. Community members are deeply divided between long-term bulls who believe in the company's underlying photonics technology and frustrated investors who are calling for management accountability and questioning the firm's transparency after news of the cancellation was delayed.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending as investors grapple with persistent downward pressure and concerns over potential dilution, despite the company's focus on its upcoming mid-size vehicle platform and continued financial backing from key institutional partners. Community sentiment remains sharply divided between long-term bulls highlighting the company's technical product advantages and skeptics who fear further share price erosion and the threat of bankruptcy or restructuring.

Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim and Kevan Shokat on July 2, 2018 and is headquartered in San Diego, CA.

Erasca Inc

Erasca (ERAS) is facing significant market volatility following an 8-K filing that disclosed a Grade 5 fatality, raising investor concerns regarding potential FDA clinical holds and long-term asset viability. Community sentiment is deeply polarized, with critics warning of toxic data and potential bankruptcy, while some long-term holders dismiss the reaction as an over-correction and advocate for buying the dip.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is trending as the community highlights the recent completion of point-to-point electric air taxi demonstration flights in New York City, which serves as a major real-world proof point for urban air mobility. Investors are actively debating the company's transition from prototype testing to infrastructure integration, with sentiment split between those focused on long-term growth catalysts and those concerned by ongoing execution challenges and stock price volatility.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently at the center of intense market attention following the release of positive Phase 3 data for its gene-editing therapy and the initiation of a rolling FDA filing. The stock is experiencing extreme volatility as retail investors debate the significance of the clinical results and the implications of a subsequent common stock offering, while the community remains sharply divided over the potential for a short squeeze given the high short interest.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is trending as investors bet on the commercial viability of its proprietary Perkinamine polymer technology, which is seen as a key solution for high-speed, energy-efficient data center and AI connectivity. Community discussions are heavily focused on the company's potential to displace legacy materials in hyperscale environments, with significant excitement surrounding upcoming industry milestones and partnerships.

Our vision is to create a global exchange using Ethereum blockchain, where everyone on this planet has the opportunity to buy and sell mobile bandwidth in any country just like you buy foreign currencies on FOREX.

DENT

DENT is currently capturing community attention as investors debate its potential for a breakout, with many highlighting its utility in the mobile data space and active development as catalysts for future growth. The community sentiment remains polarized, featuring a mix of long-term holders waiting for a significant price movement and vocal skeptics labeling the asset as a speculative pump-and-dump opportunity.

X-Energy, Inc. operates as an energy company The firm focuses on modular nuclear reactors and fuel technology for clean energy generation. The company was founded by Kam Ghaffarian and Eben Mulder on 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-energy Inc

X-energy is generating significant investor buzz following its recent IPO, fueled by strong backing from major players like Amazon and interest in its role within the burgeoning AI data center power narrative. The community is actively debating the company's valuation and long-term execution capabilities compared to other nuclear-sector peers.

Trulieve Cannabis Corp. engages in the provision of medical cannabis products and services. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis

Trulieve Cannabis is trending as the market reacts to the formal rescheduling of medical marijuana to Schedule III, a shift expected to provide significant tax relief by eliminating the Section 280E tax burden. Community discourse remains heavily focused on the company's dominant market share in Florida and anticipation that this regulatory milestone will pave the way for institutional capital and potential uplisting to major exchanges.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is trending as investors focus on aggressive supply-burn initiatives and potential regulatory tailwinds, with community sentiment fueled by active staking and the anticipation of a project revival. Traders remain divided between those viewing the asset as a speculative long-term turnaround play and others expressing skepticism given the token's volatile history.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Up  Following Analyst Upgrade

Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Up Following Analyst Upgrade...

Celldex Therapeutics (NASDAQ:CLDX) Upgraded at Barclays

Barclays raised shares of Celldex Therapeutics from an "underweight" rating to an "overweight" rating and set a $45.00 price target for the company in a report on Monday...

Celldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month High - Here's What Happened

Celldex Therapeutics (NASDAQ:CLDX) Sets New 52-Week High - Time to Buy...

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) have received a consensus rating of "Moderate Buy" from the twelve analysts that are currently covering the firm, Marketbeat.com...

Tudor Investment Corp ET AL Makes New $818,000 Investment in Celldex Therapeutics, Inc. $CLDX

Tudor Investment Corp ET AL purchased a new position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 31,618 shares of the biopharmaceutical company's stock...

Celldex Therapeutics Spotlights Barzolvolimab as Phase III CSU Data Looms After Fast Enrollment

Celldex Therapeutics (NASDAQ:CLDX) executives used an appearance at H.C. Wainwright's annual Inflammation and Skin Disease Conference to highlight the company's late-stage plans for barzolvolimab, an...

Celldex Therapeutics (NASDAQ:CLDX) Sees Unusually-High Trading Volume  - Here's Why

Celldex Therapeutics (NASDAQ:CLDX) Sees Strong Trading Volume - Here's Why...

Celldex Therapeutics (NASDAQ:CLDX) Stock Price Crosses Above 200 Day Moving Average - Should You Sell?

Celldex Therapeutics (NASDAQ:CLDX) Shares Cross Above 200-Day Moving Average - Time to Sell...

Celldex Therapeutics (NASDAQ:CLDX) Reaches New 1-Year High Following Analyst Upgrade

Celldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month High Following Analyst Upgrade...

Celldex Therapeutics (NASDAQ:CLDX) Upgraded at Wolfe Research

Wolfe Research raised shares of Celldex Therapeutics from a "peer perform" rating to an "outperform" rating and set a $44.00 price objective on the stock in a research report on Monday...

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

CLDX
Celldex Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CLDX News

CLDXCelldex Therapeutics Inc.